Zhenzhi Medicine and Abogen Biosciences Announce First-in-Human Dosing of ABOR2014 (IPM511), the World’s First mRNA Therapeutic Vaccine Encoding Nearly 20 Hepatocellular Carcinoma Antigens

BeijingZhenzhi MedicalTechnology Co., Ltd.(hereinafter referred to as "Zhenzhi Medical")AndAbogenTechnology Co., Ltd.("Abogen" hereinafter)Jointly announced,The First PatientRecently launched at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, the jointly developed project by both partiesFirstIndividualTumor Antigen mRNA Therapeutic Vaccine ABOR2014（IPM511）Receiving Treatment in Clinical Trials（ABOR2014-MSA-202301; NCT05981066）。

This study aims to evaluateABOR2014（IPM511）mRNA Therapeutic Cancer VaccinesMonotherapy and Combination Therapy with PD-1 InhibitorsProgression after first-line standard treatmentAdvanced Hepatocellular CarcinomaClinical research on the safety, tolerability, and preliminary efficacy of ABOR2014（IPM511）The Optimal Biologic Dose（OBD）Recommended dose for the expansion phase.

ABOR2014（IPM511）It is based on IMMURITHMS®, a unique tumor antigen epitope computing platform developed by Beijing Zhenzhi Medical Technology Co., Ltd., utilizing the advanced mRNA design capabilities and LNP delivery system of Abogen Biosciences' proprietary mRNA technology platform.mRNA Therapeutic Vaccine Encoding Nearly 20 High-Frequency Antigen Epitopes in Liver Cancer, the vaccine can induce the patient's own immune system to restore anti-tumor capability after intramuscular injection.

ABOR2014-MSA-202301 Principal Investigator, Chief Physician of Hepatic Surgery at Peking Union Medical College HospitalProfessor Haitao ZhaoIndicates:"We are very pleased that our team has completed the enrollment and dosing of the first patient in the ABOR2014-MSA-202301 study. ABOR2014（IPM511）Demonstrated good safety and clinical accessibility. Currently,mRNA tumor therapeutic vaccines combined with PD-1 are an exciting emerging therapy in oncology.。mRNA tumor therapeutic vaccines can induce strong tumor antigen T-cell responses, and when combined with PD-1 inhibitors, further activate T cells. This emerging therapy is expected to help address issues of drug resistance in immunotherapy or targeted-immunotherapy combination treatments for liver cancer.

ABOR2014（IPM511）World's FirstThe coding is close20 Epitopes of Liver Cancer Antigens, and it has been confirmed that these antigens are highly expressed in liver cancer patients.Based on these characteristics, it lays the foundation for the team to carry out this globally pioneering and challenging clinical research project. This study will help us better explore whether emerging drug combinations can be more effective in activating the immune system from multiple aspects, further understand the potential of mRNA tumor vaccines in treating liver cancer, and identify possible advantageous populations. It aims to provide patients with new and accessible treatment options, with the hope of changing the current status of clinical practice and becoming a new paradigm in tumor immunotherapy.

Dr. Henghui Zhang, Founder and CEO of Beijing Zhenzhi Medical Technology Co., Ltd.Stated: "Since its establishment, Zhenzhi Medical has pioneered the use of artificial intelligence/deep learning(AI/ML)The algorithm combines the research model of "tumor immunology multi-omics data + immunological biotechnology" cross-feedback to develop the IMMURITHMS® computing platform. The company uses this computing platform to establish an antigen epitope library and T-cell receptor database covering multiple solid tumors. ABOR2014（IPM511）Demonstrated exciting antigen presentation capabilities in preclinical studies,Presentation of tumor antigens on MHC I and MHC II, with the ability to activate specific CD8+ and CD4+ T cells and exhibit anti-tumor activity.We are highly anticipating the results of the ABOR2014-MSA-202301 exploratory clinical study to fully evaluate its safety, immunokinetics, and preliminary efficacy."

Ms. Wenjie Song, Chief Medical Officer of AbogenStated: "Since its establishment, Abogen has been committed to building an independent intellectual property rights platform for mRNA technology and an LNP delivery system, promoting disruptive mRNA therapeutic approaches to address disease challenges. During the COVID-19 pandemic, based on our mature mRNA platform technology capabilities, we were able to efficiently iterate and develop a series of COVID-19 mRNA products, demonstrating the development efficiency and capability of mRNA technology. We also look forward to the application of the mRNA technology platform in a broader range of disease areas, providing novel therapeutic solutions for numerous unmet clinical needs. We believe that through collaboration, linking diverse technical methods and innovative capabilities including AI and computational biology, will better unlock the potential of the mRNA technology platform. Currently,Abogen has multiple mRNA tumor candidate drugs entering the clinical research stage.We look forward to working with our partners to fully advance research progress in the safest and most scientific way, and to see mRNA therapies applied in clinical oncology as soon as possible, serving a broader patient population."